Literature DB >> 3017203

Synergism between anti-rhinovirus antivirals: various human interferons and a number of synthetic compounds.

A L Ahmad, D A Tyrrell.   

Abstract

DCF (dichloroflavan), enviroxime, chalcone Ro-09-0410 and HuIFN (Human interferon)-alpha 2, HuIFN-beta, HuIFN-beta X 401 and HuIFN-gamma, showed antiviral activity in vitro against RV2 (rhinovirus type 2) and RV9. Binary combinations of these drugs showed synergistic activity of which the combinations of HuIFN-gamma or HuIFN-alpha and enviroxime were of most interest. They were studied in more detail in tissue culture by virus yield experiments and in organ culture of human embryonic nasal epithelium and human embryonic tracheal culture in which there was a potent antiviral synergy. These results indicate that such combinations of drugs may be worthy of clinical study.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3017203     DOI: 10.1016/0166-3542(86)90005-7

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  5 in total

Review 1.  Chemotherapy of rhinovirus colds.

Authors:  S J Sperber; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

2.  Mechanism of Anti-rotavirus Synergistic Activity by Epigallocatechin Gallate and a Proanthocyanidin-Containing Nutraceutical.

Authors:  S M Lipson; G Karalis; L Karthikeyan; F S Ozen; R E Gordon; S Ponnala; J Bao; W Samarrai; E Wolfe
Journal:  Food Environ Virol       Date:  2017-05-02       Impact factor: 2.778

Review 3.  Antiviral chemotherapy and prophylaxis of viral respiratory disease.

Authors:  S J Sperber; F G Hayden
Journal:  Clin Lab Med       Date:  1987-12       Impact factor: 1.935

Review 4.  A view from the Common Cold Unit.

Authors:  D A Tyrrell
Journal:  Antiviral Res       Date:  1992-06       Impact factor: 5.970

Review 5.  The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery.

Authors:  Judith M Rollinger; Michaela Schmidtke
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.